June 21, 2024
Dr. Mikkael A. Sekeres discusses the limitations of the chemotherapy-free combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) as treatment for high-risk acute promyelocytic leukemia (APL) patients.
Read the Full article
Tags: Mikkael A. Sekeres, Sylvester Comprehensive Cancer Center